Vaxcyte, Inc. (NASDAQ:PCVX) Director Halley E. Gilbert Sells 18,200 Shares of Stock

Vaxcyte, Inc. (NASDAQ:PCVXGet Free Report) Director Halley E. Gilbert sold 18,200 shares of the company’s stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $73.00, for a total transaction of $1,328,600.00. Following the transaction, the director now owns 5,625 shares in the company, valued at $410,625. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Vaxcyte Stock Up 3.5 %

Shares of Vaxcyte stock opened at $73.44 on Thursday. The stock’s fifty day simple moving average is $66.27 and its 200 day simple moving average is $65.46. Vaxcyte, Inc. has a 12 month low of $44.20 and a 12 month high of $82.04.

Vaxcyte (NASDAQ:PCVXGet Free Report) last released its quarterly earnings results on Wednesday, May 8th. The company reported ($0.85) EPS for the quarter, topping analysts’ consensus estimates of ($1.13) by $0.28. As a group, research analysts anticipate that Vaxcyte, Inc. will post -3.96 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the stock. Teachers Retirement System of The State of Kentucky raised its holdings in shares of Vaxcyte by 16.6% during the first quarter. Teachers Retirement System of The State of Kentucky now owns 25,059 shares of the company’s stock worth $1,712,000 after acquiring an additional 3,564 shares during the period. Farallon Capital Management LLC grew its stake in shares of Vaxcyte by 11,000.0% during the 1st quarter. Farallon Capital Management LLC now owns 377,400 shares of the company’s stock worth $25,780,000 after acquiring an additional 374,000 shares in the last quarter. RA Capital Management L.P. raised its holdings in shares of Vaxcyte by 4.0% in the first quarter. RA Capital Management L.P. now owns 8,203,754 shares of the company’s stock valued at $560,398,000 after purchasing an additional 312,500 shares during the last quarter. Tidal Investments LLC bought a new stake in shares of Vaxcyte in the first quarter worth $405,000. Finally, California State Teachers Retirement System boosted its holdings in Vaxcyte by 11.8% during the first quarter. California State Teachers Retirement System now owns 92,026 shares of the company’s stock worth $6,286,000 after purchasing an additional 9,695 shares during the last quarter. Institutional investors own 96.78% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently weighed in on PCVX shares. Cantor Fitzgerald restated an “overweight” rating on shares of Vaxcyte in a report on Thursday, May 9th. Needham & Company LLC restated a “buy” rating and set a $95.00 target price on shares of Vaxcyte in a research report on Thursday, May 9th.

Read Our Latest Stock Analysis on Vaxcyte

About Vaxcyte

(Get Free Report)

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.

Read More

Insider Buying and Selling by Quarter for Vaxcyte (NASDAQ:PCVX)

Receive News & Ratings for Vaxcyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxcyte and related companies with MarketBeat.com's FREE daily email newsletter.